Claims

1. Use of a compound of Formula (I):



(I)

wherein

A is a bond, a NH, O, S, SO, SO_2, SO_2NH, PO_4, -NH-CO-NH-, -CO-NH-, -CO-, -CO-O-, -NH-CO-O-, an alkylene group, an alkenylene group, an alkinylene group, a heteroalkylene group, an arylene group, a heteroarylene group, a cycloalkylene group, a heterocycloalkylene group, an alkylarylene group or a heteroarylalkylene group or a combination of two or more of these atoms or groups;

X is CR5 or N;

Y is CR6 or N;

U is F or Cl;

n is 0, 1, 2 or 3;

R1 is H, F, Cl, Br, I, OH, NH_2, an alkyl group or a heteroalkyl group;

R2 is H, F or Cl;

R3 is H, an alkyl group, an alkenyl group, an alkinyl group, a heteroalkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an alkylaryl group or a heteroarylalkyl group;

R4 is a heteroalkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an alkylaryl group or a heteroarylalkyl group;

R5 is H, F, Cl, OH, NH_2, an alkyl group or a heteroalkyl group, or

R3 and R5 can be linked via an alkylene, an alkenylene or a heteroalkylene group or be a part of a cycloalkylene or heterocycloalkylene group, in case R3 is no H and R5 is no H, F, OH, NH_2 or Cl;

R6 is H, F, Cl or OMe;

or a pharmacologically acceptable salt, solvate, hydrate or formulation thereof for the treatment of bacterial infections at a pH lower than 7.4.

2. Use of a compound according to Claim 1, wherein R1 is H.

3. Use of a compound according to Claim 1, wherein R2 is F.

4. Use of a compound according to Claim 1, wherein R3 is an optionally substituted cyclopropyl group.

5. Use of a compound according to Claim 1, wherein R4 is an optionally substituted acetylamino group.

6. Use of a compound according to Claim 1, wherein the absolute configuration at C-5 of the oxazolidinone ring is (S) according to the Cahn-Ingold-Prelog nomenclature system.

7. Use of a compound according to Claim 1, wherein X is N or CH.

8. Use of a compound according to Claim 1, wherein Y is CF.

9. Use of a compound according to Claim 1, wherein n is 0.

10. Use of a compound according to Claim 1, wherein A is a group of the formula

$$-B_{0-1}-\left[D-E_{0-1}\right]_m-G_{0-1}-K_{0-1}-$$

wherein

the group B is NH, O, S, SO, SO_2, SO_2NH, an alkylene, which may be substituted by one, two or more fluorine atoms, or a heteroalkylene group, which may be substituted by one, two or more fluorine atoms and/or at the optionally present nitrogen atoms by an alkyl or an acyl group;

the groups D independently of each other are optionally anellated heterocycloalkylen groups with 1, 2, 3 or 4 nitrogen atoms, which heterocycloalkylen groups may each be substituted by one, two or more fluorine atoms and/or which each may be substituted at one, two, three or four nitrogen atoms by an alkyl or an acyl group;

the groups E independently of each other are an alkylene, which may be substituted by one, two or more fluorine atoms, an O, S, SO, SO_2, SO_2NH group, or a heteroalkylen group, which may be substituted by one, two or more fluorine atoms and/or at the optionally present nitrogen atoms by an alkyl or an acyl group;

the group G contains one or more optionally anellated heterocycloalkylene groups with 1, 2, 3 or 4 nitrogen atoms, which heterocycloalkylene groups may each be substituted by one, two or more fluorine atoms and/or which each may be substituted at one, two, three or four nitrogen atoms by an alkyl or an acyl group;

the group K is an alkylene, which may be substituted by one, two or more fluorine atoms, an O, S, SO, SO_2, SO_2NH group, or a heteroalkylene group, which may be substituted by one, two or more fluorine atoms and/or at the optionally present nitrogen atoms by an alkyl or an acyl group; and m = 1,2,3 or 4.

11. Use of a compound according to Claim 1, wherein A is a group of the formula -V-W-, wherein V is a direct bond or

a group of the formula NH, O, S, SO, SO_2, SO_2NH, PO_4, -NH-CO-NH-, -CO-NH-, -CO-, $-CH_2-$, -CO-O-, $-(CH_2)_{1-3}-O-$, -CH=CH-C(O)-, or -NH-CO-O- and W is a heterocycloalkyl group with 4 to 7 ring atoms or a alkylheterocycloalkyl group with 4 to 7 ring atoms and 1 to 4 carbon atoms in the alkyl chain, all these groups may be substituted by 1, 2, 3 or 4 fluorine atoms, methyl or methoxy groups.

12. Use of a compound according to Claim 1, wherein A is a group of the formula



wherein

V is a group of the formula NH, O, S, SO, SO_2, SO_2NH, PO_4, -NH-CO-NH-, -CO-NH-, -CO-, $-CH_2-$, -CO-O-, $-(CH_2)_{1-3}-O-$, -CH=CH-C(O)-, or -NH-CO-O-; a is 0, 1, 2, 3 or 4; b is 0, 1, 2, 3 or 4; c is 0, 1, 2, 3 or 4 and 1, 2, 3 or 4 hydrogen atoms may be substituted by F, a methyl- or a methoxy group.

13. Use of a compound according to Claim 12, wherein V is NH, O, S, SO or SO_2.

14. Use of a compound according to Claim 12, wherein V is O or NH; a is 0 or 1; b is 1 or 2 and c is 1 or 2.

15. Use of a compound according to Claim 1, wherein A is selected from the following groups which may be

substituted by one, two or more fluorine atoms or by an alkyl group which may be substituted by one or more fluorine atoms, and wherein the amino groups may be substituted by an alkyl or an acyl group:





16. A pharmaceutical composition containing a compound according to Claim 1 and optionally carriers and/or adjuvants and/or diluents.

17. Pro-drugs which contain a compound according to Claim 1 and at least one pharmacologically acceptable protective group.

18. Use of a compound, a pharmaceutical composition or a pro-drug according to Claim 1 for the manufacture of medicaments for the treatment of bacterial infections in environments having a pH < 7.4, preferably < 7.0.

19. Use of a compound, a pharmaceutical composition or a pro-drug according to Claim 1 for the manufacture of medicaments for the treatment of bacterial infections in inflamed tissues and/or abscesses.